Statistical analysis of cost-effectiveness data / / Andrew R. Willan, Andrew H. Briggs

• Record Nr.: UNINA9911020014103321
• Autore: Willan Andrew Roger <1947->
• Pubbl/distr/stampa: Chichester, England ; ; Hoboken, NJ, : John Wiley, c2006
• ISBN: 9786610649945; 9781280649943; 1280649941; 9780470856284; 0470856289; 9780470856277; 0470856270
• Descrizione fisica: 1 online resource (212 p.)
• Collana: Statistics in practice
• Altri autori (Persone): BriggsAndrew H
• Disciplina: 658.1554015195
• Soggetti: Cost effectiveness - Statistical methods
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references (p. [183]-192) and indexes.
• Nota di contenuto: Statistical Analysis of Cost-effectiveness Data; Contents; Preface; 1 Concepts; 1.1 Introduction; 1.2 Cost-Effectiveness Data and the Parameters of Interest; 1.3 The Cost-Effectiveness Plane, the ICER and INB; 1.4 Outline; 2 Parameter Estimation for Non-Censored Data; 2.1 Introduction; 2.2 Cost; 2.2.1 Sample Means for Estimating Incremental Cost; 2.2.2 Using Multiple Regression Models; 2.2.3 Transformation (and the Retransformation Problem); 2.2.4 Generalized Linear Models; 2.2.5 Two-Part Models for Excess Zeros; 2.2.6 Cost Prediction Models; 2.3 Effectiveness; 2.3.1 Probability of Surviving; 2.3.2 Mean Survival Time2.3.3 Mean Quality-Adjusted Survival Time; 2.3.4 Mean Quality-Adjusted Survival: Controlling for Baseline Utility; 2.4 Summary; 3 Parameter Estimation for Censored Data; 3.1 Introduction; 3.2 Mean Cost; 3.2.1 Direct (Lin) Method; 3.2.2 Inverse-Probability Weighting; 3.3 Effectiveness; 3.3.1 Probability of Surviving; 3.3.2 Mean Survival Time; 3.3.3 Mean Quality-Adjusted Survival Time; 3.4 Summary; 4 Cost-Effectiveness Analysis; 4.1 Introduction; 4.2 Incremental Cost-Effectiveness Ratio; 4.3 Incremental Net Benefit; 4.4 ; The Cost-Effectiveness Acceptability Curve; 4.5 Using Bootstrap Methods4.6 A Bayesian Incremental Net Benefit Approach; 4.7 Kinked Thresholds; 4.8 Summary; 5 Cost-Effectiveness Analysis: Examples; 5.1 Introduction; 5.2 The CADET-Hp Trial; 5.3 Symptomatic Hormone-Resistant Prostate Cancer; 5.4 The Canadian Implantable Defibrillator Study (CIDS); 5.5 The EVALUATE Trial; 5.6 Bayesian Approach Applied to the UK PDS Study; 5.7 Summary; 6 Power and Sample Size Determination; 6.1 Introduction; 6.2 Approaches Based on the Cost-Effectiveness Plane; 6.2.1 Briggs and Gray; 6.2.2 Willan and O'Brien; 6.2.3 Gardiner et al.; 6.3 The Classical Approach Based on Net Benefit6.3.1 The Method; 6.3.2 Example; 6.4 Bayesian Take on the Classical Approach; 6.4.1 The Method; 6.4.2 Example; 6.5 The Value of Information Approach; 6.5.1 The Method; 6.5.2 Example; 6.6 Summary; 7 Covariate Adjustment and Sub-Group Analysis; 7.1 Introduction; 7.2 Non-Censored Data; 7.2.1 Example, Non-Censored Data; 7.3 Censored Data; 7.3.1 Cost; 7.3.2 Quality-Adjusted Survival Time; 7.3.3 Survival Time; 7.3.4 The Canadian Implantable Defibrillator Study (CIDS); 7.3.5 The Evaluate Trial; 7.4 Summary; 8 Multicenter and Multinational Trials; 8.1 Introduction8.2 Background to Multinational Cost-Effectiveness; 8.3 Fixed Effect Approaches; 8.3.1 Willke et al.; 8.3.2 Cook et al.; 8.4 Random Effects Approaches; 8.4.1 Aggregate Level Analysis: Multicenter Trials; 8.4.2 Aggregate Level Analysis: Multinational Trials; 8.4.3 Hierarchical Modeling; 8.5 Summary; 9 Modeling Cost-Effectiveness; 9.1 Introduction; 9.2 A General Framework for Modeling Cost-Effectiveness Results; 9.3 Case Study: An Economic Appraisal of the Goal Study; 9.3.1 The GOAL Study; 9.3.2 Standard Approach to Estimating Cost-Effectiveness; 9.3.3 An Alternative Approach to Estimating Cost-Effectiveness
• Sommario/riassunto: The statistical analysis of cost-effectiveness data is becoming increasingly important within health and medical research. Statistical Analysis of Cost-Effectiveness Data provides a practical book that synthesises the huge amount of research that has taken place in the area over the last two decades. Comprising an up-to-date overview of the statistical analysis of cost-effectiveness data, the book is supported by numerous worked examples from the author's own experience. It has been written in a style suitable for medical statisticians and health care professionals alike. Key features